Most recent papers in the journal Lancet Oncology

#1

JOURNAL ARTICLE

New junk food legislation in Colombia.

Talha Burki

No abstract text is available yet for this article.

37980916

November 16, 2023: Lancet Oncology

#2

REVIEW

The future of cancer care in the UK-time for a radical and sustainable National Cancer Plan.

Ajay Aggarwal, Ananya Choudhury, Nicola Fearnhead, Pam Kearns, Anna Kirby, Mark Lawler, Sarah Quinlan, Carlo Palmieri, Tom Roques, Richard Simcock, Fiona M Walter, Pat Price, Richard Sullivan

Cancer affects one in two people in the UK and the incidence is set to increase. The UK National Health Service is facing major workforce deficits and cancer services have struggled to recover after the COVID-19 pandemic, with waiting times for cancer care becoming the worst on record. There are severe and widening disparities across the country and survival rates remain unacceptably poor for many cancers. This is at a time when cancer care has become increasingly complex, specialised, and expensive. The current crisis has deep historic roots, and to be reversed, the scale of the challenge must be acknowledged and a fundamental reset is required...

37977167

November 14, 2023: Lancet Oncology

#3

JOURNAL ARTICLE

Development and validation of age-specific risk prediction models for primary ovarian insufficiency in long-term survivors of childhood cancer: a report from the Childhood Cancer Survivor Study and St Jude Lifetime Cohort.

Cindy Im, Zhe Lu, Sogol Mostoufi-Moab, Angela Delaney, Lin Yu, Jessica L Baedke, Yutong Han, Yadav Sapkota, Yutaka Yasui, Eric J Chow, Rebecca M Howell, Smita Bhatia, Melissa M Hudson, Kirsten K Ness, Gregory T Armstrong, Paul C Nathan, Yan Yuan

BACKGROUND: Female survivors of childhood cancer are at risk for primary ovarian insufficiency (POI), defined as the cessation of gonadal function before the age of 40 years. We aimed to develop and validate models to predict age-specific POI risk among long-term survivors of childhood cancer. METHODS: To develop models to predict age-specific POI risk for the ages of 21-40 years, we used data from the Childhood Cancer Survivor Study (CCSS). Female survivors aged 18 years or older at their latest follow-up, with self-reported menstrual history information and free of subsequent malignant neoplasms within 5 years of diagnosis, were included...

37972608

November 13, 2023: Lancet Oncology

#4

JOURNAL ARTICLE

Cancer care in Nepal after earthquake.

Manjulika Das

No abstract text is available yet for this article.

37952543

November 9, 2023: Lancet Oncology

#5

JOURNAL ARTICLE

Last cancer hospital in Gaza.

Talha Burki

No abstract text is available yet for this article.

37952542

November 9, 2023: Lancet Oncology

#6

JOURNAL ARTICLE

Optimising follow-up strategy based on cytology and human papillomavirus after fertility-sparing surgery for early stage cervical cancer: a nationwide, population-based, retrospective cohort study.

Teska N Schuurman, Mirte Schaafsma, Kaylee H To, Viola M J Verhoef, Karolina Sikorska, Albert G Siebers, Hans H B Wenzel, Maaike C G Bleeker, Eva Maria Roes, Ronald P Zweemer, Peggy J de Vos van Steenwijk, Refika Yigit, Jogchum J Beltman, Petra L M Zusterzeel, Christianne A R Lok, Ruud L M Bekkers, Constantijne H Mom, Nienke E van Trommel

BACKGROUND: The optimal follow-up strategy to detect recurrence after fertility-sparing surgery for early stage cervical cancer is unknown. Tailored surveillance based on individual risks could contribute to improved efficiency and, subsequently, reduce costs in health care. The aim of this study was to establish the predictive value of cervical cytology and high-risk human papillomavirus (HPV) testing to detect recurrent cervical intraepithelial neoplasia grade 2 or worse (CIN2+; including recurrent cervical cancer) after fertility-sparing surgery...

37952541

November 9, 2023: Lancet Oncology

#7

JOURNAL ARTICLE

Artificial intelligence-based pathology as a biomarker of sensitivity to atezolizumab-bevacizumab in patients with hepatocellular carcinoma: a multicentre retrospective study.

Qinghe Zeng, Christophe Klein, Stefano Caruso, Pascale Maille, Daniela S Allende, Beatriz Mínguez, Massimo Iavarone, Massih Ningarhari, Andrea Casadei-Gardini, Federica Pedica, Margherita Rimini, Riccardo Perbellini, Camille Boulagnon-Rombi, Alexandra Heurgué, Marco Maggioni, Mohamed Rela, Mukul Vij, Sylvain Baulande, Patricia Legoix, Sonia Lameiras, Léa Bruges, Viviane Gnemmi, Jean-Charles Nault, Claudia Campani, Hyungjin Rhee, Young Nyun Park, Mercedes Iñarrairaegui, Guillermo Garcia-Porrero, Josepmaria Argemi, Bruno Sangro, Antonio D'Alessio, Bernhard Scheiner, David James Pinato, Matthias Pinter, Valérie Paradis, Aurélie Beaufrère, Simon Peter, Lorenza Rimassa, Luca Di Tommaso, Arndt Vogel, Sophie Michalak, Jérôme Boursier, Nicolas Loménie, Marianne Ziol, Julien Calderaro

BACKGROUND: Clinical benefits of atezolizumab plus bevacizumab (atezolizumab-bevacizumab) are observed only in a subset of patients with hepatocellular carcinoma and the development of biomarkers is needed to improve therapeutic strategies. The atezolizumab-bevacizumab response signature (ABRS), assessed by molecular biology profiling techniques, has been shown to be associated with progression-free survival after treatment initiation. The primary objective of our study was to develop an artificial intelligence (AI) model able to estimate ABRS expression directly from histological slides, and to evaluate if model predictions were associated with progression-free survival...

37951222

November 8, 2023: Lancet Oncology

#8

JOURNAL ARTICLE

An HPV vaccine from India: broadening possibilities for cervical cancer control.

John T Schiller, Aimée R Kreimer

No abstract text is available yet for this article.

37949087

November 7, 2023: Lancet Oncology

#9

JOURNAL ARTICLE

Immunogenicity and safety of a new quadrivalent HPV vaccine in girls and boys aged 9-14 years versus an established quadrivalent HPV vaccine in women aged 15-26 years in India: a randomised, active-controlled, multicentre, phase 2/3 trial.

Hitt Sharma, Sameer Parekh, Pramod Pujari, Sunil Shewale, Shivani Desai, Neerja Bhatla, Smita Joshi, Sharmila Pimple, Anand Kawade, Latha Balasubramani, Anitha Thomas, Vanita Suri, Sanjay Lalwani, Rajini Uday, Veena Kamath, Ranajit Mandal, A Rajeswar, Abraham Peedicayil, Usha Rani Poli, Dipanwita Banerjee, Rengaswamy Sankaranarayanan, Partha Basu, Richard Muwonge, Sunil Gairola, Vikas Dogar, Harish Rao, Umesh Shaligram

BACKGROUND: To meet global cervical cancer elimination efforts, a wider range of affordable and accessible vaccines against human papillomavirus (HPV) are needed. We aimed to evaluate the immunogenicity and safety of a quadrivalent HPV vaccine (targeting HPV types 6, 11, 16, and 18), developed and manufactured by the Serum Institute of India (SIIPL). Here we report outcomes in the 9-14 years cohort. METHODS: This randomised, active-controlled, phase 2/3 trial was conducted at 12 tertiary care hospitals across India...

37949086

November 7, 2023: Lancet Oncology

#10

JOURNAL ARTICLE

Performance of the WID-qEC test versus sonography to detect uterine cancers in women with abnormal uterine bleeding (EPI-SURE): a prospective, consecutive observational cohort study in the UK.

Iona Evans, Daniel Reisel, Allison Jones, Alba Bajrami, Simrit Nijjar, Sarah Annie Solangon, Rupali Arora, Elisa Redl, Lena Schreiberhuber, Isma Ishaq-Parveen, Julia Rothärmel, Chiara Herzog, Davor Jurkovic, Martin Widschwendter

BACKGROUND: To detect uterine cancer, simpler and more specific index tests are needed to triage women with abnormal uterine bleeding to a reference histology test. We aimed to compare the performance of conventional index imaging tests with the novel WID-qEC DNA methylation test in terms of detecting the presence or absence of uterine cancers in women with abnormal uterine bleeding. METHODS: EPI-SURE was a prospective, observational study that invited all women aged 45 years and older with abnormal uterine bleeding attending a tertiary gynaecological diagnostic referral centre at University College London Hospital (London, UK) to participate...

37944542

November 6, 2023: Lancet Oncology

#11

JOURNAL ARTICLE

Fixed-duration ibrutinib-venetoclax versus chlorambucil-obinutuzumab in previously untreated chronic lymphocytic leukaemia (GLOW): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial.

Carsten U Niemann, Talha Munir, Carol Moreno, Carolyn Owen, George A Follows, Ohad Benjamini, Ann Janssens, Mark-David Levin, Tadeusz Robak, Martin Simkovic, Sergey Voloshin, Vladimir Vorobyev, Munci Yagci, Loic Ysebaert, Keqin Qi, Qianya Qi, Pierre Sinet, Lori Parisi, Srimathi Srinivasan, Natasha Schuier, Kurt Baeten, Angela Howes, Donne Bennett Caces, Arnon P Kater

BACKGROUND: In the GLOW study, fixed-duration ibrutinib-venetoclax showed superior progression-free survival versus chlorambucil-obinutuzumab in patients with previously untreated chronic lymphocytic leukaemia who were older or had comorbidities, or both, at a median follow up of 27·7 months. In this Article, we report updated outcomes from GLOW after a 46-month median follow-up. METHODS: GLOW was a randomised, multicentre, phase 3 study done at 67 hospital centres across 14 countries...

37944541

November 6, 2023: Lancet Oncology

#12

JOURNAL ARTICLE

Long-term efficacy of ibrutinib-venetoclax for first-line treatment in chronic lymphocytic leukaemia.

Anna Fink

No abstract text is available yet for this article.

37944540

November 6, 2023: Lancet Oncology

#13

JOURNAL ARTICLE

Non-invasive DNA methylation-based testing for the diagnosis of endometrial cancer.

Jessica St Laurent, Kevin M Elias

No abstract text is available yet for this article.

37944539

November 6, 2023: Lancet Oncology

#14

JOURNAL ARTICLE

HPV vaccine roll-out in Nigeria and Bangladesh.

Munyaradzi Makoni

No abstract text is available yet for this article.

37931625

November 3, 2023: Lancet Oncology

#15

JOURNAL ARTICLE

IASLC calls for clinical trials to use tobacco use data.

Bryant Furlow

No abstract text is available yet for this article.

37926102

November 2, 2023: Lancet Oncology

#16

JOURNAL ARTICLE

Proposal to lower Australia's bowel screening age limit from 50 to 45 years.

Tony Kirby

No abstract text is available yet for this article.

37926101

November 2, 2023: Lancet Oncology

#17

JOURNAL ARTICLE

Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer (UK TACT2; CRUK/05/19): quality of life results from a multicentre, phase 3, open-label, randomised, controlled trial.

Galina Velikova, James P Morden, Joanne S Haviland, Charlotte Emery, Peter Barrett-Lee, Helena Earl, David Bloomfield, Adrian Murray Brunt, Peter Canney, Robert Coleman, Mark Verrill, Andrew Wardley, Gianfilippo Bertelli, Paul Ellis, Rob Stein, Judith M Bliss, David Cameron

BACKGROUND: Adjuvant chemotherapy for patients with early breast cancer improves outcomes but its toxicity affects patients' quality of life (QOL). The UK TACT2 trial investigated whether accelerated epirubicin improves time to recurrence and if oral capecitabine is non-inferior to cyclophosphamide, methotrexate, and fluorouracil (CMF) for efficacy with less toxicity. Results showed no benefit for accelerated epirubicin and capecitabine was non-inferior. As part of the QOL substudy, we aimed to assess the effect of chemotherapies on psychological distress, physical symptoms, and functional domains...

37926100

November 2, 2023: Lancet Oncology

#18

JOURNAL ARTICLE

Improving access to surgery for childhood cancer.

Lars Hagander

No abstract text is available yet for this article.

37924824

November 1, 2023: Lancet Oncology

#19

JOURNAL ARTICLE

Global cancer surgery: a vital service to eliminate false economy.